Senior Management Team
Senior Management Team

Michael A. Narachi

President and Chief Executive Officer

READ BIOGRAPHY

Michael A. Narachi has served as our President and Chief Executive Officer and a member of our board of directors since March 2009. Previously, Mr. Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., a leading therapeutics company, where he served as General Manager of Amgen’s Anemia Business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN® Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He currently serves on the board of directors of Ultragenyx Pharmaceutical, Inc. Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles. Mr. Narachi also currently serves as the Chair of the Emerging Companies Section Governing Board of BIO, the Biotechnology Industry Organization.

CLOSE

Thomas Cannell

Chief Operating Officer and President of Global Commercial Products

READ BIOGRAPHY

Thomas Cannell joined Orexigen after 27 years at Merck where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management. At Merck, Tom’s assignments included President of Merck Canada (2012 – 2014) and Head of Marketing and Strategy for MSD Japan (2010-2012). Earlier he served in general manager roles for a U.S. sales division, as leader of a Merck business unit, managing a multi-billion dollar product portfolio and thousands of employees, and as General Manager, New Commercial Model, U.S., where he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Tom holds a Bachelor of Science degree in Veterinary Science and a Doctor of Veterinary Medicine degree from Washington State University. He has also served in the U.S. Army Reserves (currently inactive) since 1987.

CLOSE

Thomas Lynch

EVP, Chief Administrative Officer, General Counsel & Corporate Secretary

READ BIOGRAPHY

Thomas Lynch is a veteran legal professional with more than a decade of experience in the life sciences industry as well as six years of general corporate practice. He is responsible for the company’s global legal affairs and compliance operations. Tom joined Orexigen from Novartis where, since 2012, he served as senior legal counsel in two divisions, including leading global legal and compliance support for Novartis Pharma’s neuroscience franchise and advising on business development and alliance management with partners in Europe, Japan and the U.S. Earlier, Lynch spent almost ten years with Boston Scientific in a variety of legal roles and nearly six years practicing corporate law at Dorsey & Whitney LLP. He holds a juris doctorate degree from Boston College Law School, a master’s degree in teaching from the University of St. Thomas, and a bachelor’s degree in history from Stanford University.

CLOSE

Peter Flynn

EVP, Global Head of Development

READ BIOGRAPHY

Peter Flynn joined Orexigen in 2015 and leads global development, regulatory and safety. Pete has over 15 years of biotechnology industry experience. Previously, Pete was Senior Vice President, Early Program Development at Fate Therapeutics, where he was responsible for development of programs and platforms and was a member of the senior team that took the company through an IPO in 2013. Prior to Fate he was Vice President of Research at Ren Pharmaceuticals. Pete started his industry career as one of the first employees at the antibody therapeutics company KaloBios Pharmaceuticals, where as head of biochemistry he helped build both the platform technology and pipeline. Pete holds a BSc in Molecular Biology from University College London, a Ph.D in Biochemistry from Imperial Cancer Research Fund (CRUK) and was a postdoctoral fellow at the University of California, San Francisco.

CLOSE

Monica Forbes

VP, Chief Financial Officer

READ BIOGRAPHY

Monica Forbes joined Orexigen in 2014 and is currently Vice President and Chief Financial Officer. Over the last 3.5 years, Monica has made tremendous contributions to the organization, guiding the development and oversight of the company’s budget process, supporting the financial planning and analysis for the U.S. business and working with the executive team on our strategic outreach process. Monica has over 15 years of financial planning & analysis experience in the biopharmaceutical and telecommunications industries. She joined Orexigen from Amylin where she served as an Associate Director, Financial Business Partner leading financial planning and reporting activities for a $300M division. Prior to that, Monica held a variety of finance roles at Invitrogen, Ericsson and Qualcomm. Monica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University.

CLOSE